Representing multinational pharma company in trademark oppositions. Our firm is assisting Eugia Pharma with trademark oppositions filed by Mega Lifesciences and Neolpharma Perú regarding the client’s pharmaceutical products. Our work comprises designing a strategy to defend the client’s trademark EUGIA in Peru and seek trademark registration.
Pharmaceutical products belonging to different drug categories: Mega Lifesciences filed an opposition concerning its trademarks EUGICA and EUGICA HERBAL INFUSION—which refer to nutritional supplements and herbal remedies—, registered in class 5 (pharmaceutical products), against the client’s trademark EUGIA—related to an injectable drug. Neolpharma, in turn, filed an opposition based on its trademark ZEUGIAL —a medication for the treatment of neuropathic disease.
Demonstrating coexistence of brands and lack of confusion among consumers: Our defence arguments consist of demonstrating i) the trademarks are not similar and will not lead to confusion among consumers and ii) different trademarks coexist in the same class, including the term EUGICA. They could coexist with the term EUGIA in their composition, such as ZEUGIAL, NEUGINA, LEUGINASA, and EUGERIAL trademarks, which are owned by different trademark holders.
Pharmaceutical group with strong presence in over 100 markets worldwide: Eugia is an India-based pharmaceutical company that provides affordable and accessible specialised products, including general injectables, oncology medications, ophthalmics, and hormonal products. With a strong presence in more than 120 countries, it has over 250 globally approved generics focused on enhancing healthcare outcomes.
Essential role in ensuring trademark protection for globally renowned brand: This is a crucial case for the client as it relates to its globally recognised EUGIA brand. Our role is to ensure brand integrity, which is vital for patient safety and trust in medication efficacy.
Latest development: The Peruvian Trademark Office issued resolutions determining that both Mega Lifesciences’ and Neolpharma’s opposition are unfounded. Neolpharma Perú appealed and the procedure is pending.
